SNY - Sanofi

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
44.92
-0.03 (-0.07%)
As of 11:19AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close44.95
Open44.88
Bid44.90 x 800
Ask44.91 x 2200
Day's Range44.84 - 45.04
52 Week Range40.00 - 47.11
Volume227,616
Avg. Volume1,488,829
Market Cap113.103B
Beta (3Y Monthly)0.41
PE Ratio (TTM)23.15
EPS (TTM)1.94
Earnings DateN/A
Forward Dividend & Yield1.74 (3.87%)
Ex-Dividend Date2019-05-07
1y Target Est52.00
Trade prices are not sourced from all markets
  • CVS suspends sales of Zantac during safety review
    Yahoo Finance Video

    CVS suspends sales of Zantac during safety review

    Heartburn drug Zantac is facing new scrutiny after CVS pulled the products from shelves over a possible link to cancer. Yahoo Finance's Jared Blikre joins Alexis Christoforous on The Ticker to discuss.

  • New Sanofi CEO Looks to Shake Things Up
    GuruFocus.com

    New Sanofi CEO Looks to Shake Things Up

    Paul Hudson is examining the organization from top to bottom with the goal of developing a strategy to put the company on the road to success Continue reading...

  • Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag
    Zacks

    Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag

    Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.

  • Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study
    Zacks

    Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study

    Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema.

  • Hedge Funds Are In Wait And See Mode With Sanofi (SNY)
    Insider Monkey

    Hedge Funds Are In Wait And See Mode With Sanofi (SNY)

    Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • Zacks

    J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case

    Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.

  • Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry
    Zacks

    Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry

    Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.

  • Verastem's (VSTM) Copiktra Gets Orphan Drug Designation
    Zacks

    Verastem's (VSTM) Copiktra Gets Orphan Drug Designation

    Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.

  • Wall Street Loves These “Strong Buy” Dividend Stocks
    TipRanks

    Wall Street Loves These “Strong Buy” Dividend Stocks

    Stock go up, investor happy. Stock go down, investor... sad?Probably. In fact, we'd go so far as to say that's probably the ordinary reaction an investor has to a decline in the share price of a stock he or she owns -- but not all the time.You see, if the stock is question is a dividend stock, even a decline in stock price can be offset by the value of the dividend you're being paid to own it. What's more, because a stock's dividend yield is calculated by dividing the dividend amount by the stock price, the lower the stock price falls, the bigger the dividend yield becomes -- making the stock increasingly attractive to other dividend investors, and providing a backstop that can prevent the stock falling further!So how do you find great dividend stocks, popular on Wall Street, and attractive to dividend investors?Using the Stock Screener at TipRanks, you can screen for stocks rated "strong buy" by Wall Street analysts, and screen, too, for stocks paying better-than-average dividend yields. Combine these two attributes, and voila! You've got a great dividend stock candidate. Here are three of them:Sanofi (SNY) One of Europe's largest drugmakers, Paris-based Sanofi boasts a market capitalization north of $112 billion, more than $40 billion in annual sales, and net profits approaching $4 billion. Sanofi stock's a great cash generator as well, throwing off nearly $6.3 billion in cash over the last 12 months, enabling it to pay a market-beating dividend yield of 3.9%.Just recently, Morgan Stanley analyst Mark Purcell upgraded Sanofi shares to "overweight," calling the stock a "defensive" play in an uncertain market. According to Purcell, the stock is "largely de-risked" -- indeed, the analyst says Sanofi has the lowest risk growth outlook of any European Big Pharma stock, due to a lack of big drugs losing patent protection in the near future (the dreaded "patent cliff"), and a pipeline of new drugs in late-stage clinical trials that could soon come to market.Whereas the consensus on Wall Street is that Sanofi stock is worth $52 per share, Purcell thinks Sanofi could go all the way to ... $98 a share! (To watch Purcell's track record, click here)"We argue that new CEO Paul Hudson inherits significant optionality to unlock shareholder value alongside the recent CFO and CSO appointments. The management team can draw on their shared experience from the strategic transformations of AstraZeneca and Novartis, the new chapter of innovation at Roche and the cost discipline of Peugeot. The evolution of the GSK equity story, with which Sanofi has much in common, albeit with greater balance sheet flexibility and lower patent risk, offers a further yardstick for investors, we believe. We explore potential strategic options that could in theory help to close the 15% relative P/E multiple discount," Purcell said.Sanofi stock hasn't moved much over the past year, up less than 4%. Regardless, Wall Street loves Sanofi stock, rating it "strong buy" on average, and with a $52 price target implying 14.5% upside from today's prices. Factor in the dividend, and you're pushing 18.5% potential profit. (See Sanofi stock analysis on TipRanks)Merck (MRK) But you needn't travel all the way to Europe to find an attractive drug stock paying a big dividend. Right here at home, Kenilworth, New Jersey-based Merck & Co. pays its shareholders a very respectable 2.7% dividend yield. (The average stock on the S&P 500 is only paying 2%).Recently, Merck presented more positive data at ESMO supporting the use of Keytruda + chemo to treat neoadjuvant/adjuvant TNBC. These data, along with other data presented at ESMO, like BMY's (NC) Merck-227 data and the Lynparza ovarian data, support MRK's leadership in oncology.Morgan Stanley analyst David Risinger commented, "KN-522 demonstrated an impressive pathologic complete response (pCR), improving on results from its earlier exploratory KN-173 trial. On another key efficacy metric, event free survival (EFS), the trend to 18mo looks quite favorable but the trial’s discussant urged a measure of caution in over-interpreting the findings, saying data were too early still and need to mature. The reason for caution is that discontinuation rates were ~2x for Keytruda vs placebo (PBO), raising the specter that longer-term survival curves may look different than shown at the first, early look, if too many patients are stopping therapy prematurely. The discussant also reminded that certain immune-related adverse events would likely be permanent, implying a more definitive calculation of risk:benefit is warranted, but this is not yet possible from the preliminary data set."As a result, Risinger reiterated an Overweight rating on MRK stock with $90 price target, which implies nearly 7% upside from current levels. (Watch Risinger's track record, click here)Overall, the consensus targets on the Street see Merck shares rising as high as $100 per share over the next 12 months, 18% above current levels. (See Merck stock analysis on TipRanks)Verizon (VZ) Switching gears now from the somewhat esoteric world of biotech to a company we're all very familiar with, Verizon is our final stock to look at in today's column -- and for good reason.Investors have long viewed the telecom industry as a happy hunting ground for stocks paying robust dividends, and Verizon, which pays 4.2%, is no exception. In fact, Verizon has raised its dividend for 13 years in a row, with its latest dividend hiking coming just last month. At 4.2%, Verizon's dividend is now more than twice the market average.One analyst who likes Verizon more than most is Oppenheimer's Timothy Horan, who in August upgraded Verizon shares to "outperform" with a $70 price target implying better than 16% upside (and better than 20% with the dividend added in). Horan believes that Verizon will be an early beneficiary of the telecommunications industry's move to 5G wireless technology. And anticipating customer defections from T-Mobile and Sprint once those two companies merge, Horan predicts that Verizon will also benefit from customer "churn" at this wireless rival. (To watch Horan's track record, click here)Overall, Wall Street loves the stock, giving Verizon "strong buy" ratings by and large. Granted, with a consensus price target of "only" $65, most analysts don't see a huge amount of upside in the stock -- only about 9%. But if you add in the dividend yield, the potential profit on this one exceeds 13%, and maybe even more.Topping it all off, with a P/E of less than 16, Verizon's not just the biggest dividend payer on today's list of highly-rated dividend stocks -- it's also the cheapest. (See Verizon stock analysis on TipRanks)

  • Business Wire

    Hagens Berman: Law Firm Taking on Drug Makers in Zantac Class Action Condemns FDA’s “Reckless” Cover-up of Ranitidine Carcinogen

    Class-action law firm Hagens Berman which filed the first lawsuit regarding Sanofi and Boehringer Ingelheim’s intentionally concealed cancer risks in its popular heartburn medication, Zantac, has issued a fact sheet to set the record straight about what attorneys are calling glaring incompetence and shameful conduct from the FDA to date in connection with Zantac. “The FDA’s response with respect to Zantac, in our opinion, is a public disservice and constitutes reckless behavior for an agency tasked with protecting the people,” said Steve Berman, managing partner of Hagens Berman and attorney leading the case for consumers. “The FDA has become a shell of an agency.

  • Sanofi (EPA:SAN) Has A Pretty Healthy Balance Sheet
    Simply Wall St.

    Sanofi (EPA:SAN) Has A Pretty Healthy Balance Sheet

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • Walgreens (WBA) Becomes Latest Retailer to Suspend Zantac Sales
    Zacks

    Walgreens (WBA) Becomes Latest Retailer to Suspend Zantac Sales

    Walgreens (WBA) announced today that they would be suspending the sales of Sanofi's (SNY) heartburn medication Zantac.

  • Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study
    Zacks

    Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study

    Pfizer's (PFE) investigational eczema candidate abrocitinib meets all co-primary and secondary endpoints as a monotherapy in the second pivotal late stage study.

  • New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer
    PR Newswire

    New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer

    PARIS, Sept. 30, 2019 /PRNewswire/ -- Data published today in the New England Journal of Medicine showed that patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and who progressed within 12 months on an androgen receptor (AR)-targeted agent (abiraterone or enzalutamide) experienced significantly longer radiographic progression free survival (rPFS) with Jevtana® (cabazitaxel) plus prednisone compared with abiraterone plus prednisone or enzalutamide. Overall survival (OS) with Jevtana was also significantly longer.

  • CVS pulls Zantac and its generic brand over possible cancer link
    CBS MoneyWatch

    CVS pulls Zantac and its generic brand over possible cancer link

    The FDA said people shouldn't panic, but suggests switching to another over-the-counter drug while the agency tests more samples

  • SNY or NVO: Which Is the Better Value Stock Right Now?
    Zacks

    SNY or NVO: Which Is the Better Value Stock Right Now?

    SNY vs. NVO: Which Stock Is the Better Value Option?

  • Buy These 3 Stocks With Upgraded Broker Ratings Right Now
    Zacks

    Buy These 3 Stocks With Upgraded Broker Ratings Right Now

    After thorough research, brokers decide to rate a particular company's stock. Hence, one can be easily rely on the rating.

  • GuruFocus.com

    Foreign Firms Recognized as Hottest Biotechs

    For the first time since FierceBiotech issued its list, companies outside the US are included Continue reading...

  • Sanofi Canada receives Gold-Level Parity Certification
    CNW Group

    Sanofi Canada receives Gold-Level Parity Certification

    LAVAL, QC, Sept. 26, 2019 /CNW Telbec/ - Sanofi Canada is pleased to announce that the company has reached a great milestone: our first Parity Certification from the Women in Governance organization. This certification means that Sanofi Canada has taken its place among notable Canadian companies that strive towards gender parity.

  • Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late
    Zacks

    Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late

    Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

  • Here's Why AstraZeneca (AZN) is Outperforming Its Industry
    Zacks

    Here's Why AstraZeneca (AZN) is Outperforming Its Industry

    AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

  • After Shingles Standout, Glaxo Hunts for the Next Vaccines
    Bloomberg

    After Shingles Standout, Glaxo Hunts for the Next Vaccines

    (Bloomberg) -- GlaxoSmithKline Plc is taking aim at a virus that causes serious lung infections and kills tens of thousands of children each year, hoping to replicate the success of its last blockbuster vaccine.Experimental shots targeting respiratory syncytial virus, or RSV, are the top pipeline priority for Glaxo’s vaccines unit, Emmanuel Hanon, its research and development head, said in an interview. Glaxo plans to move those vaccines into the final stage of testing by the end of 2020, he said.“This represents a massive opportunity, provided we can deliver,” Hanon said.Glaxo isn’t the only company racing to deliver an RSV vaccine, a goal that has eluded scientists for about half a century. Drugmakers including Johnson & Johnson and Sanofi are also working on potential shots against the virus, which is estimated to cause as many as 200,000 deaths a year across the globe.The vaccine is one of the keys to the British drugmaker’s ambitions to build on Shingrix, the shingles shot forecast to generate sales of about $1.8 billion this year. While Glaxo’s pharma unit garners most of the attention, vaccines are set to play a bigger role as the company moves ahead with plans to separate its consumer health division.Glaxo is keen to expand in the realm of therapeutic vaccines, used after an infection occurs, and to speed up the development of new shots, a journey that can take 15 years, Hanon said. The company sees an opportunity to do it in half as much time partly by harnessing new technologies that enhance the immune system’s response to vaccines.“That’s our ambition,” he said. “Fifteen years is too long.”Next StoryVaccines have already helped Glaxo counter generic competition for Advair, the company’s aging mega-drug for asthma. The unit’s sales climbed 25% in the first half of the year to 3.1 billion pounds ($3.8 billion). The drugmaker is providing a vaccines update at an event for investors Thursday. Glaxo shares rose 1.8% in London trading. “The business is of increasing significance for them,” said Emmanuel Papadakis, an analyst at Barclays in London. Investors will likely focus on its plans to expand Shingrix capacity and “the next story on the pipeline side.”Drugmakers appear to be making progress in pursuit of an RSV shot. Sanofi’s new Chief Executive Officer Paul Hudson earlier this month cited the French company’s experimental vaccine as one of its most promising opportunities.Almost all children get an RSV infection by the time they are two years old, according to the U.S. Centers for Disease Control and Prevention. While it mostly causes mild, cold-like illnesses, it can lead to more serious problems, such as pneumonia and bronchiolitis, infections of the lungs and airways.Among therapeutic vaccines, Glaxo is also developing a product to prevent a lung disease called chronic obstructive pulmonary disease from worsening due to bacteria. The company hopes to have data to show the vaccine works by the second half of next year, Hanon said.(Updates with other drugmakers working on RSV vaccine in fourth paragraph.)To contact the reporter on this story: James Paton in London at jpaton4@bloomberg.netTo contact the editors responsible for this story: Eric Pfanner at epfanner1@bloomberg.net, Marthe FourcadeFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Protalix Completes Enrollment in Third Fabry Disease Study
    Zacks

    Protalix Completes Enrollment in Third Fabry Disease Study

    Protalix (PLX) completes enrollment in another phase III study of pegunigalsidase alfa (PRX 102) to treat Fabry disease.

  • Moving Average Crossover Alert: Sanofi
    Zacks

    Moving Average Crossover Alert: Sanofi

    Sanofi (SNY) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.